DuPont Pioneer and Vilnius University Announce CRISPR-Cas Patent Grant

PRWeb – DuPont Pioneer and Vilnius University today confirmed that the United States Patent and Trademark Office granted U.S. Patent Number 9,637,739 to Vilnius University for its broad claims relating to CRISPR-Cas technology. A team of scientists, led by Professor Virginijus Siksnys, from the Vilnius University Institute of Biotechnology was one of the first groups to discover that Cas9 proteins could be repurposed to precisely edit targeted sections of DNA to achieve a specific outcome.

“Our team is very pleased to receive a U.S. patent in recognition of our pioneering work demonstrating that Cas9 functions as a programmable nuclease for gene editing applications,” said Siksnys.

“We congratulate Dr. Siksnys and the Institute of Biotechnology of Vilnius University for being awarded this patent which acknowledges significant contributions to the CRISPR-Cas field,” said Neal Gutterson, vice president, Research and Development for DuPont Pioneer, the advanced plant genetics business of DuPont. “The Vilnius intellectual property is an important part of our IP portfolio for the use of CRISPR-Cas technology in agriculture.”

Read more at PRWeb.